Press releases

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the second quarter 2017 report. ”It is gratifying that our pivotal Phase III study OCEAN commenced during the quarter, according to our strategic plan. This is a milestone for Ygalo® and for us as a company, and takes

Stockholm - June 14, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the first patient has been dosed in the pivotal phase III study OCEAN. The study is targeting Late-Stage Relapsed Refractory (RRMM) patients with Multiple Myeloma. The study is designed as a head-to-head comparative study where the result will show whether Ygalo® is more effective, just as effective, or less effective than the current standard of care treatment option pomalidomide for late-stage RRMM patients

Stockholm, Sweden – 18 May 2017 — Oncopeptides AB’s (ONCO) annual general meeting 2017 was held today, at IVA Conference center in Stockholm. At the meeting, the following principal resolutions were passed

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2017 report. ”Our IPO received strong interest both from Sweden and internationally, including several well-renowned institutional long term investors. We are now fully financed to drive our broad clinical development program in late-stage multiple myeloma patients, including a phase II trial to be initiated and the ongoing phase II trials and the pivotal phase III trial OCEAN.”

For the 11th time, SwedenBIO Award was awarded on Wednesday night

During April, the number of shares and votes in Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has increased by 977 906 shares and votes due to the new issue of shares that was made in connection with the exercise of the over-allotment option, subsequent to the listing of the Company’s

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438 (“Oncopeptides” or the “Company”), are hereby given notice to attend the Annual General Meeting to be held in the Banquet room at IVA Conference center, Grev Turegatan 16, Stockholm, Sweden, Thursday 18 May 2017 at 4.00 p.m. Coffee will be served starting at 3.00 p.m., at which time the registration for attendees will commence

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN

Stockholm - March 22, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the composition of the Nomination Committee has now been completed